NIH funds research on Stimuli, Effects, and Treatment of Tricuspid Valve Maladaptation

The National Heart Lung and Blood Institute of the National Institutes of Health has funded our $3.5 million R01 proposal on “Tricuspid Valve Maladaptation: Its Stimuli, its Effect on Valve Function, and its Response to Therapy”.

Leakage of the tricuspid valve, which is located between the right atrium and right ventricle, is extremely common and, if not treated, can significantly impact the health of patients. The current gold-standard for treatment is a surgical approach known as tricuspid annuloplasty, which unfortunately does not have high long-term success rates and fails in approximately one-third of patients. This proposal is relevant to public health as we aim to better understand a new tricuspid valve disease mechanism, tricuspid valve maladaptation, that could be used as future therapeutic target toward improving the currently poor outcomes for patients with tricuspid valve regurgitation.

Further details about the grant can be found here.